BSD Medical is Now Pyrexar Medical

China is making significant strides in cancer treatment, positioning itself as a global leader in hyperthermia therapy. The Affiliated Zhongshan Hospital of Dalian University, a 2200-bed facility, is at the forefront of this movement. Specializing in advanced medical fields such as oncology radiotherapy, bone microsurgery, and hepatobiliary surgery, the hospital has recently launched a comprehensive Hyperthermia Center within its expansive 22-acre campus.

The Hyperthermia Center, established in March 2021, currently operates 13 hyperthermia devices and plans to expand to 20 by the end of 2024. This expansion will make it the largest oncological hyperthermia center in China, setting a new standard in cancer treatment.

Pyrexar BSD-2000 Deep Regional Hyperthermia System

The center offers cutting-edge therapies that combine hyperthermia with chemotherapy and radiotherapy. The hospital is a center for research and Innovative treatments for advanced solid tumors. Results from several novel approaches aim to improve survival rates and enhance the quality of life for patients battling advanced tumors.

Acknowledgment to our distribution partners at Dalian Orientech Co., Ltd. for their hard work in making this center possible.

The CME-accredited educational program offered by the University of Maryland, School of Thermal Oncology is now open for registration.

The last session drew an international crowd, including physicians from South Korea, Poland, and Japan, as well as prominent cancer centers here in the U.S. The feedback we received, was that this was a five-star educational program, valuable to any member of a thermal oncology team.  Topics covered all aspects of practice management, patient treatment, physics, and workflow. Practice managers shared how adding thermal oncology to their services increased overall revenue by over 19%.  This information is essential for centers that want to add hyperthermia systems but require cost justification to receive purchase approval.

Pyrexar Medical continues to support educational outreach from organizations like the University of Maryland, Society of Thermal Medicine, European Society for Hyperthermic Oncology, and similar institutions that strive to move forward hyperthermia research in the treatment of cancer. The CME course outline can be found here.

The ESHO 35 (European Society of Hyperthermic Oncology) just wrapped up in Cologne, Germany last week. Representing Pyrexar at the event was the team from Dr. Sennewald Medizintechnik. Dr. Sennewald is the primary sponsor of this year's event and has supported this event since its founding.

The event was held at the KOMED event center in the MediaPark in downtown Cologne. The conference included two days of lectures and presentations covering all aspects of thermal therapy advancements. It is often an opportunity for researchers to present status updates on ongoing projects.  Dr. Dario Rogriques, Assistant Professor of Radiation Oncology at the University of Maryland School of Medicine presented the details of an upcoming animal study for the Pyrexar Hal.o head applicator for the treatment of glioblastoma.

Dr. Rodriques's program objective is to evaluate numerically the feasibility of focused heating in the minipig brain using the noninvasive MR-compatible brain applicator (Hal.o) and assess the feasibility of partial brain heating to design blood perfusion measurement experiments to improve the accuracy of temperature simulations using large mammal data.  A full-scale prototype has been built and tested to verify heating performance.

The First Annual Department of Radiation Oncology Research Symposium was held at the University of Maryland's Medical School Teaching Facility. The symposium gives faculty, residents, and student researchers the opportunity to showcase their research projects.

Dario Rodrigues, Ph.D., Assistant Professor in the Radiation Oncology department, placed first place in the poster category.  His poster summarized the work he has been doing to verify the use of Pyrexar's Hal.o applicator, a Non-Invasive, Non-Ionizing Radiation approach to produce a focused heat zone in the brain.

It has been demonstrated in a study published in the International Journal of Radiation Biology & Physics (Sneed, 1998 Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme) that hyperthermia can boost the effectiveness of radiotherapy when treating glioblastoma.  Pyrexar Engineering has been working on an applicator to provide focused hyperthermia under MR guidance for several years.  Dr. Rodrigues is currently developing a study protocol to begin animal studies. 

Join us in recognizing Dr. Rodrigues for his accomplishments.